Conceptos Categóricos

Crónicas de autores

Francisco J Morales-Olivas *

Autor invitado por SIIC


ESTUDIO DE SEGURIDAD POSCOMERCIALIZACION DE IRBESARTAN EN HIPERTENSOS

Estudio de seguridad de irbesartán en los primeros pacientes tratados con el fármaco en España

*Francisco J Morales-Olivas
describe para SIIC los aspectos relevantes de su trabajo
THE KARTAN STUDY: A POSTMARKETING ASSESSMENT OF IRBESARTAN IN PATIENTS WITH HYPERTENSION
Clinical Therapeutics,
26(2):232-244 Feb, 2004

Esta revista, clasificada por SIIC Data Bases, integra el acervo bibliográfico
de la Biblioteca Biomédica (BB) SIIC.

Institución principal de la investigación
*Departamento de Farmacología Facultad de Medicina y Odontología Universidad de Valencia Valencia, España, Valencia, España
Imprimir nota
Referencias bibliográficas
1. Chalmers D, Dombey SL, Lawson DH. Post marketing surveillance of captopril (for hypertension): A preliminary report. Br J Clin Pharmacol. 1987;24:343-349. 2. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: Current perspectives and future needs. JAMA. 1999;281:824-829. 3. Kaplan NM. The CARE Study: A postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin Ther. 1996;18:658-670. 4. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2446. 5. Larochelle P, Flack JM, Marbury TC, et al. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter
Investigators. Am J Cardiol. 1997;80:1613-1615. 6. Coca A, Calvo C, García-Puig J, et al. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: The
MAPAVEL Study. Clin Ther. 2002;24:126-138. 7. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637-645. 8. Reeves RA, Lin CS, Kassler-Taub K, Pouleur H. Doserelated efficacy of irbesartan for hypertension: An integrated analysis. Hypertension. 1998;31:1311-1316. 9. Simon TA, Gelarden RT, Freitag SA, et al. Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am J Cardiol. 1998;82:179-182. 10. Lacourcière Y. A multicenter, randomized, doubleblind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged 65 years with mild to moderate hypertension. Clin Ther. 2000;22:1213-1224. 11. Markham A, Spencer CM, Jarvis B. Irbesartan: An updated review of its use in cardiovascular disorders. Drugs. 2000;59:1187-1206. 12. World Health Organization (WHO) Guidelines Subcommittee. 1999 WHO-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens. 1999;17:151-183. 13. WHO. International drug monitoring: The role of national centres. Technical Report Series WHO. 1972;498. 14. Karvea® [summary of product characteristics]. Madrid, Spain: Bristol-Myers Squibb Group; 1998. 15. Speirs C, Wagniart F, Poggi L. Perindopril postmarketing surveillance: A 12-month study in 47,351 hypertensive patients. Br J Clin Pharmacol. 1998;46:63-70. 16. Morton V, Torgerson DJ. Effect of regression to the mean on decision making in health care. BMJ. 2003; 326:1083-1084. 17. Lim PO, Nys M, Naas AA, et al. Irbesartan reduces QT dispersion in hypertensive patients. Hypertension. 1999;33:713-718. 18. Lacourcière Y, Lefebvre J. Modulation of the reninangiotensin-aldosterone system and cough. Can J Cardiol. 1995;11(Suppl F):33F-39F. 19. Mackay FJ, Pearce GL, Mann RD. Cough and
angiotensin II receptor antagonists: Cause or confounding? Br J Clin Pharmacol. 1999;47:111-114. 20. Rawlins MD, Thompson JW: Mechanisms of adverse drug reactions. In: Davies DM. Textbook of Adverse Drug Reactions. 4th ed. New York: Oxford University Press; 1991:18. 21. Gambini D, Sala F, Gianotti R, Cusini M. Exanthematous reaction to irbesartan. J Eur Acad Dermatol Venereol. 2003; 17:472-473. 22. Anderson JA. Allergic reactions to drugs and biological agents. 1992;268:2844-2857.
23. Pool JL, Guthrie RM, Littlejohn TW III, et al. Doserelated antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens. 1998;11:462-470. 24. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf. 1999;21:23-33.
25. Mann RD, Mackay F, Pearce G, et al. Losartan: A study of pharmacovigilance data on 14,522 patients. J Hum Hypertens. 1999;13:551-557.


ua40317
-->